The Pharmacy Times® Neurology resource center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.
What can we help you find?
Study findings provide further basis for dietary interventions as future treatments for disorders such as multiple sclerosis.
The release of generic versions of brand name drugs for patients with multiple sclerosis had little overall effect on the price increase.
The diazepam nasal spray was granted 7 years of Orphan Drug Exclusivity by the FDA Office of Orphan Products Development.
Patients with epilepsy treated with perampanel during routine clinical care had favorable retention rates and sustained efficacy.
An analysis of efficacy and safety outcomes in patients receiving perampanel as first adjunctive antiepileptic drug found that almost half of the patients were seizure-free.
In this study, researchers wanted to evaluate the frequency of reduced immunoglobulin concentrations and its association with immunotherapy and disease course in 2 independent cohorts with multiple sclerosis.
Fingolimod treats relapsing forms of multiple sclerosis in adult patients.
Riluzole oral film (Exservan, Aquestive Therapeutics) has received early-action approval from the FDA for the treatment of amyotrophic lateral sclerosis.
Approved by the FDA in May 2019, midazolam nasal spray CIV (Nayzilam, UCB) is the first nasal rescue treatment for seizure clusters in the United States.
If approved, risdiplam (Genentech) would be the first at-home administered medicine for patients living with spinal muscular atrophy.
Top news of the day from across the health care landscape.
Officials with the FDA have approved adalimumab-afzb (Abrilada, Pfizer), a biosimilar to Humira, for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn disease, ulcerative colitis, and plaque psoriasis.